HCW Biologics Q2 FY26 net loss widens to $5.2 million; revenue rises to $135,568
Reuters2026/08/14 19:15- HCW Biologics posted Q2 net loss of USD 5.2 million, widening from USD 1.9 million a year earlier.
- Revenue climbed to USD 135,568 from USD 6,550; R&D held at USD 1.2 million while G&A fell 11% to USD 1.9 million.
- Six-month revenue rose to USD 6.7 million from USD 11,615, driven by closing the Trimmune License for HCW11-006 in vivo rights.
- HCW9302 Phase 1 alopecia areata study showed early SALT score improvements in cohort two; no dose-limiting toxicities reported.
- Management said HCW9302’s CD25 targeting supports regulatory T-cell expansion; full Phase 1 readout remains slated for Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tiger Global reduced holdings in tech giants in Q2 and bet on “new stars”: built positions in Cerebras (CBRS.US), AMD (AMD.US), SpaceX (SPCX.US), increased holdings in Intel (INTC.US), and exited Netflix (NFLX.US).
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Tiger Global has submitted its 13F report on holdings for the second quarter ending June 30, 2026.
Sequoia Logistica authorizes release of Q2 2026 interim financial statements
ethena transferred 81.97 million USDC from a certain exchange wallet to FalconX
Crypto prices
More
